Toxicity of the antimalarial artemisinin and its dervatives
Top Cited Papers
- 16 February 2010
- journal article
- review article
- Published by Taylor & Francis Ltd in Critical Reviews in Toxicology
- Vol. 40 (5), 405-421
- https://doi.org/10.3109/10408441003610571
Abstract
As long as no effective malaria vaccine is available, chemotherapy belongs to the most important weapons fighting malaria. One of the most promising new drug developments is the sesquiterpene artemisinin (ARS) and its derivatives, e.g., artemether, arteether, and sodium artesunate. Large clinical studies and meta-analyses did not show serious side effects, although proper monitoring of adverse effects in developing countries might not be a trivial task. There is a paucity of large-scale clinical trials suitable to detect rare but significant toxicity. Therefore, a final and definitive statement on the safety of artemisinins still cannot be made. In contrast, animal experiments show considerable toxicity upon application of artemisinins. In the present review, the authors give a comprehensive overview on toxicity studies in cell culture and in animals (mice, rats, rabbits, dogs, monkeys) as well as on toxicity reported in human clinical trials. The authors emphasize the current knowledge on neurotoxicity, embryotoxicity, genotoxicity, hemato- and immunotoxicity, cardiotoxicity, nephrotoxicity, and allergic reactions. The lesson learned from animal and human studies is that long-term availability rather than short-term peak concentrations of artemisinins cause toxicity. Rapid elimination of artemisinins after oral intake represents a relatively safe route of administration compared to delayed drug release after intramuscular (i.m.) injection. This explains why considerable toxicities were found in the majority of animal experiments, but not in human studies. In addition, there are drug-related differences, i.e., intramuscular application of artemether or arteether, but not to artesunate, which is safe and gives good profiles after i.m. administration in severe malaria. Although there is no need to increase doses of artemisinins for uncomplicated malaria, this has to be taken into account for cerebellar involvement in severe malaria. It might also be important in determining dose limitations for treatment of other diseases such as cancer.Keywords
This publication has 98 references indexed in Scilit:
- Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trialThe Lancet, 2009
- Monitoring and evaluation of malaria in pregnancy – developing a rational basis for controlMalaria Journal, 2008
- Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cellsNitric Oxide, 2008
- Monitoring antimalarial safety and tolerability in clinical trials: A case study from UgandaMalaria Journal, 2008
- Pharmacovigilance in developing countriesBMJ, 2007
- Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistanceTrends in Molecular Medicine, 2006
- Selection of Plasmodium falciparum pfmdr1 Alleles following Therapy with Artemether-Lumefantrine in an Area of Uganda where Malaria Is Highly EndemicAntimicrobial Agents and Chemotherapy, 2006
- Artemisinins target the SERCA of Plasmodium falciparumNature, 2003
- A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malariaTransactions of the Royal Society of Tropical Medicine and Hygiene, 2001
- The toxicity of artemisinin and related compounds on neuronal and glial cells in cultureChemico-Biological Interactions, 1995